Low-Dose Chest Computed Tomography Screening for Lung Cancer in Survivors of Hodgkin's Disease

This study has been terminated.
(lower than expected accrual)
Sponsor:
Collaborator:
Brigham and Women's Hospital
Information provided by (Responsible Party):
Andrea K. Ng, MD, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT00601146
First received: January 15, 2008
Last updated: August 13, 2012
Last verified: August 2012
  Purpose

This research study is being done because patients with a history of chest radiation treatment for Hodgkin's disease have been shown to be at increased risk for developing lung cancer a number of years out from treatment. The risk appears to be further increased among patients with a smoking history. Currently, the practice is to recommend annual low-dose chest CT scans in survivors of Hodgkin's disease who have received prior chest radiation treatment and who have at least a moderate smoking history. In this study, the CT scans will be read and interpreted by the study radiologist, and the results recorded in a consistent manner.


Condition Intervention
Lung Cancer
Procedure: chest computed tomography scan

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Low-Dose Chest Computed Tomography Screening for Lung Cancer in Survivors of Hodgkin's Disease

Resource links provided by NLM:


Further study details as provided by Dana-Farber Cancer Institute:

Primary Outcome Measures:
  • To prospectively collect data on chest CT screening for patients at increase lung-cancer risk after Hodgkin's disease. [ Time Frame: 3 years ] [ Designated as safety issue: No ]

Enrollment: 39
Study Start Date: November 2006
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Intervention Details:
    Procedure: chest computed tomography scan
    Once a year for three years
    Other Name: CT scan
Detailed Description:

- Participants will undergo a chest computed tomography (CT) scan once a year for a 3-year period.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Survivors of Hodgkin's disease seen for follow-up at the Brigham and Women's Hosptial Department of Radiation Oncology, the Lance Armstrong Adult Survivorship Clinic and the David B. Perini Jr. Childhood Cancer Survivor Clinic at the Dana Farber-Cancer Institute

Criteria

Inclusion Criteria:

  • 5 years or longer from initial Hodgkin's disease diagnosis
  • Current age 18 or older
  • Received mediastinal irradiation and/or alkylating-agent based chemotherapy
  • Smoking history of 10-pack years or more, or current smoker
  • Pre-approval from the participant's insurance company for the CT study

Exclusion Criteria:

  • Patients with a history of lung cancer
  • Currently receiving treatment for another cancer diagnosis
  • Known diagnosis of any metastatic cancer
  • Pregnant women
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00601146

Locations
United States, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Dana-Farber Cancer Institute
Brigham and Women's Hospital
Investigators
Principal Investigator: Andrea K. Ng, MD Dana-Farber Cancer Institute/Brigham and Women's Hospital
  More Information

No publications provided

Responsible Party: Andrea K. Ng, MD, Radiation Oncologist, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier: NCT00601146     History of Changes
Other Study ID Numbers: 06-122
Study First Received: January 15, 2008
Last Updated: August 13, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by Dana-Farber Cancer Institute:
Hodgkin's disease
CT scan

Additional relevant MeSH terms:
Hodgkin Disease
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lung Diseases
Respiratory Tract Diseases
Lung Neoplasms
Lymphoma
Neoplasms by Histologic Type
Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site

ClinicalTrials.gov processed this record on April 15, 2014